IP Library Granted Patent US 7,119,110
Granted Patent B2
US 7,119,110 · App. 10/265,093 · Granted Oct 10, 2006

Method and composition for preventing or reducing the symptoms of insulin resistance syndrome

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,119,110
App. No.
10/265,093
Granted
Oct 10, 2006
Kind
B2
Abstract

A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.

Claims (33)

1. A method for reducing the symptoms of insulin resistance in a person, the method comprising:

identifying a person suffering from or at risk for suffering from the symptoms; and

administering a composition comprising an effective amount of chromium bound to niacin and three compounds selected from the group consisting of (−) hydroxycitric acid, zinc, trans-resveratrol, gymnemic acid, selenium, an anthocyanidin, allicin and fenugreek that, when administered to the person, reduces the symptoms of insulin resistance.

2. A method as defined in claim 1 , wherein the step of administering an amount of the composition incorporates administering a composition containing between about 50 and about 1000 μg chromium which is bound to niacin.

3. A method as defined in claim 1 , wherein the step of administering comprises administering the composition in two doses per day.

4. A method as defined in claim 1 , wherein the amount of the (−) hydroxycitric acid in the composition is between about 250 and about 3000 mg.

5. A method as defined in claim 1 , wherein the amount of zinc in the composition is between about 5 and about 50 mg.

6. A method as defined in claim 1 , wherein the amount of trans-resveratrol the composition is between about 5 and about 100 mg.

7. A method as defined in claim 1 , wherein the amount of gymnemic acid in the composition is between about 50 and about 200 mg.

8. A method as defined in claim 1 , wherein the amount of selenium in the composition is between about 0.025 mg and about 0.1 mg.

9. A method as defined in claim 1 , wherein the amount of an anthocyanidin in the composition is between about 5 and about 100 mg.

10. A method as defined in claim 1 , wherein the amount of allicin in the composition is between about 2 and about 8 mg.

11. A method as defined in claim 1 , wherein the amount of fenugreek in the composition is between about 100 and about 300 mg.

12. A method for reducing the symptoms of insulin resistance in a person, the method comprising:

identifying a person suffering from or at risk for suffering from the symptoms; and

administering a composition comprising an effective amount of chromium bound to niacin and zinc and two compounds selected from the group consisting of (−) hydroxycitric acid, trans-resveratrol gymnemic acid, selenium, an anthocyanidin, allicin and a saponin that, when administered to the person, reduces the symptoms of insulin resistance; wherein the amount of zinc in the composition is between:

about 5 mg and about 50 mg.

13. A method for reducing the symptoms of insulin resistance in a person, the method comprising:

identifying a person suffering from or at risk for suffering from the symptoms; and

administering a composition comprising an effective amount of chromium bound to niacin and trans-resveratrol and two compounds selected from the group consisting of (−) hydroxycitric acid, zinc, gymnemic acid, selenium, an anthocyanidin, allicin and a saponin that, when administered to the person, reduces the symptoms of insulin resistance; wherein the amount of trans-resveratrol in the composition is between:

about 5 mg and about 50 mg.

14. A method for reducing the symptoms of insulin resistance in a person, the method comprising:

identifying a person suffering from or at risk for suffering from the symptoms; and

administering a composition comprising an effective amount of chromium bound to niacin and selenium and two compounds selected from the group consisting of (−) hydroxycitric acid, trans-resveratrol gymnemic acid, zinc, an anthocyanidin, allicin and a saponin that, when administered to the person, reduces the symptoms of insulin resistance; wherein the amount of selenium in the composition is between:

about 5 mg and about 50 mg.

15. A method for reducing the symptoms of insulin resistance in a person, the method comprising:

identifying a person suffering from or at risk for suffering from the symptoms; and

administering a composition comprising an effective amount of chromium bound to niacin, an anthocyanidin and two compounds selected from the group consisting of (−) hydroxycitric acid, trans-resveratrol, gymnemic acid, selenium, zinc, allicin and a saponin that, when administered to the person, reduces the symptoms of insulin resistance; wherein the amount of an anthocyanidin in the composition is between:

about 5 mg and about 50 mg.

16. A method for reducing the symptoms of insulin resistance in a person, the method comprising:

identifying a person suffering from or at risk for suffering from the symptoms; and

administering a composition comprising an effective amount of chromium bound to niacin and allicin and two compounds selected from the group consisting of (−) hydroxycitric acid, trans-resveratrol, gymnemic acid, selenium, an anthocyanidin, zinc and a saponin that, when administered to the person, reduces the symptoms of insulin resistance; wherein the amount of allicin in the composition is between:

about 5 mg and about 50 mg.

Assignments (5)
CHANGE OF NAME Recorded Oct 15, 2021
From: INTERHEALTH NUTRACEUTICALS INCORPORATED
To: LONZA CONSUMER HEALTH INC.
Reel/Frame 057828/0594 →
RELEASE OF SECURITY INTEREST Recorded Oct 5, 2016
From: MADISON CAPITAL FUNDING LLC
To: INTERHEALTH NUTRACEUTICALS INCORPORATED
Reel/Frame 040234/0538 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Sep 12, 2016
From: MADISON CAPITAL FUNDING LLC, AS ADMINISTRATIVE AGENT
To: INTERHEALTH NUTRACEUTICALS INCORPORATED
Reel/Frame 040068/0687 →
SECURITY AGREEMENT Recorded Dec 2, 2013
From: INTERHEALTH NUTRACEUTICALS INCORPORATED
To: MADISON CAPITAL FUNDING LLC (AS ADMINISTRATIVE AGENT)
Reel/Frame 031748/0036 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2003
From: BAGCHI, DEBASIS; PREUSS, HARRY G.; KOTHARI, SHIL C.
To: INTERHEALTH NUTRACEUTICALS INCORPORATED
Reel/Frame 013876/0069 →